Lantern Pharma Receives IND Clearance From FDA Enabling Phase 1 Initiation For Drug Candidate LP-284 In Non-Hodgkin's Lymphomas
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma has received IND clearance from the FDA, enabling Phase 1 initiation for drug candidate LP-284 in Non-Hodgkin's Lymphomas. This is the second IND clearance for Lantern in the last 100 days. The drug, developed using Lantern's AI platform, RADR®, has the potential to improve outcomes for 40,000 to 80,000 patients annually, with a global market potential of $4 billion.
September 18, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma's FDA clearance for Phase 1 initiation of LP-284 could potentially improve outcomes for a significant number of patients and tap into a $4 billion market. This is a positive development for the company.
The FDA clearance allows Lantern Pharma to proceed with Phase 1 trials for LP-284. This is a significant step forward in the drug's development process and opens up a potential $4 billion market for the company. This news is likely to be viewed positively by investors and could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100